

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the shares in Alibaba Health Information Technology Limited.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

**RESULTS OF THE SPECIAL GENERAL MEETING
HELD ON NOVEMBER 6, 2015**

The board of directors (the “**Board**”) of Alibaba Health Information Technology Limited (the “**Company**”) is pleased to announce that on November 6, 2015, the Company held a special general meeting (the “**Special General Meeting**”), at which all resolutions set out in the notice of the Special General Meeting dated October 20, 2015 were duly passed by way of poll.

Reference is made to the circular (the “**Circular**”) of the Company dated October 20, 2015. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE SGM

The Board is pleased to announce that at the Special General Meeting held at Prestige & Leadership Meeting Room, Regus Business Centre, 35/F Central Plaza, 18 Harbour Road, Wanchai, Hong Kong at 10:30 a.m. on Friday, November 6, 2015, the ordinary resolutions set out in the notice of the Special General Meeting (the “**Notice**”) dated October 20, 2015 (the “**Resolutions**”) were duly passed by way of poll. The poll results in respect of the Resolutions were as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (%)	
		For	Against
1.	(a) To approve and confirm the conditional grant of restricted share units (“ RSUs ”) to the following persons in accordance with the terms of the share award scheme adopted by the Company on November 24, 2014 (the “ Share Award Scheme ”), subject to all applicable laws, rules, regulations and the applicable award document(s) (the “ Conditional RSU Grant ”):		
	(i) 1,284,000 RSUs to Mr. WANG Lei, the Chief Executive Officer and an executive director of the Company, and a director of Alibaba Health Technology (Beijing) Company Limited and CITIC 21CN (China) Technology Company Limited, both a subsidiary of the Company;	5,302,188,256 (97.79%)	120,007,444 (2.21%)
	(ii) 758,000 RSUs to Mr. MENG Changan, a director of Alibaba Health Technology (Beijing) Company Limited and CITIC 21CN (China) Technology Company Limited, both a subsidiary of the Company;	5,302,188,256 (97.79%)	120,007,444 (2.21%)
	(iii) 852,000 RSUs to Ms. MA Li, a director of Alibaba Health Technology (Beijing) Company Limited, a subsidiary of the Company;	5,302,188,256 (97.79%)	120,007,444 (2.21%)
	(iv) 568,000 RSUs to Mr. WANG Peiyu, a director of CITIC 21CN (China) Technology Company Limited, a subsidiary of the Company.	5,302,188,256 (97.79%)	120,007,444 (2.21%)

ORDINARY RESOLUTIONS		Number of Shares Voted (%)	
		For	Against
(b)	To authorize any one or more of the directors of the Company (the “ Directors ”) to exercise the powers of the Company to allot and issue the ordinary shares of the Company pursuant to the Conditional RSU Grant (the “ Award Shares ”) under the specific mandate granted to the Directors by the shareholders of the Company at the special general meeting of the Company held on November 24, 2014 in accordance with the terms the Share Award Scheme, such that the Award Shares shall rank <i>pari passu</i> in all respects among themselves and with the existing ordinary shares in issue at the date of the allotment and issuance of the Award Shares, and that he/she/they, be and is/are hereby authorized to take such actions, do such things, which in their opinion may be necessary, desirable or expedient for the purpose of giving effect to and/or to implement the transactions contemplated in this Resolution 1.	5,304,523,086 (97.83%)	117,672,614 (2.17%)

Notes:

- (1) The full text of the Resolutions is set out in the Notice.
- (2) As at the date of the Special General Meeting:
 - (a) the total number of Shares in issue was 8,172,644,639;
 - (b) to the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, none of the Connected Grantees and their associates holds any Shares and accordingly except for the unvested options they hold in respect of a total of 12,936,000 underlying Shares in the Company as disclosed in the Circular, no Shareholder was required to abstain from voting on the Resolutions at the Special General Meeting in accordance with the Listing Rules;
 - (c) the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions at the Special General Meeting was 8,172,644,639 (representing 100% of the total issued Shares); and
 - (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the Special General Meeting was nil.
- (3) Tricor Secretaries Limited, the Company’s branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the Special General Meeting for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of Resolutions (1), Resolutions (1) were duly passed as ordinary resolutions of the Company.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
WANG Lei
Chief Executive Officer and Executive Director

Hong Kong, November 6, 2015

As at the date of this announcement, the Board comprises nine directors, of which (i) two are executive Directors, namely Ms. CHEN Xiao Ying and Mr. WANG Lei; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. TSAI Chung, Joseph, Mr. HUANG Aizhu and Mr. KANG Kai; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.